Regentis Biomaterials Ltd.
Market Cap
$13.26M
P/E Ratio
-0.14
EPS
$-24.16
Dividend Yield
—
52-Week Range
$3.00 — $8.35
Volume
10.12K
Avg Volume
20.42K
Beta
0.00
P/E (TTM)
-0.14
Forward P/E
—
PEG Ratio
—
P/S (TTM)
—
P/B (TTM)
—
P/FCF
—
EV/EBITDA
—
EV/Sales
—
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
3.94M
Float
2.37M
Free Float %
60.24%
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
IL
Exchange
AMEX
IPO Date
2025-09-11
Employees
—
CEO
Ehud Geller
Index Membership
—
Website
https://www.regentis.co.il
Regentis Biomaterials Ltd. (RGNT) is a healthcare company in the medical - instruments & supplies industry listed on the AMEX. With a market capitalization of $13.26M, a P/E ratio of -0.14, RGNT is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare RGNT against other stocks using dozens of fundamental and technical filters.
Regentis Biomaterials Ltd. (RGNT) has a trailing twelve-month (TTM) P/E ratio of -0.14. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Regentis Biomaterials Ltd. (RGNT) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Regentis Biomaterials Ltd. (RGNT) has a market capitalization of $13.26 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.